Literature DB >> 18687293

Role of lipoxin in the modulation of immune response during infection.

Fabiana S Machado1, Julio Aliberti.   

Abstract

Pro-inflammatory mediators such as IL-12, IFN-gamma and TNF are essential in controlling parasite growth during Toxoplasma gondii infection. However, it is clear that the exacerbate production of these cytokines results in the host tissue damage. Investigation into the immune response modulation during infectious disease, has revealed that lipoxin (LXA), an anti-inflammatory eicosanoids, plays an important role in regulation of immune response to different pathogens, including T. gondii and Mycobacterium tuberculosis. Here, we review the pro-resolution pathways triggered by LXA that are responsible for control of pro-inflammatory response during chronic disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18687293     DOI: 10.1016/j.intimp.2008.01.001

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

1.  Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury.

Authors:  Le Wu; Sen Miao; Lin-Bing Zou; Ping Wu; Hua Hao; Ke Tang; Pan Zeng; Jing Xiong; Hong-Hua Li; Qiang Wu; Lei Cai; Du-Yun Ye
Journal:  J Mol Neurosci       Date:  2012-06-03       Impact factor: 3.444

2.  Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection.

Authors:  Cristian Cilloniz; Mary J Pantin-Jackwood; Chester Ni; Alan G Goodman; Xinxia Peng; Sean C Proll; Victoria S Carter; Elizabeth R Rosenzweig; Kristy J Szretter; Jacqueline M Katz; Marcus J Korth; David E Swayne; Terrence M Tumpey; Michael G Katze
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  5-Lipoxygenase negatively regulates Th1 response during Brucella abortus infection in mice.

Authors:  Júlia Silveira Fahel; Mariana Bueno de Souza; Marco Túlio Ribeiro Gomes; Patricia P Corsetti; Natalia B Carvalho; Fabio A V Marinho; Leonardo A de Almeida; Marcelo V Caliari; Fabiana Simão Machado; Sergio Costa Oliveira
Journal:  Infect Immun       Date:  2015-01-12       Impact factor: 3.441

Review 4.  Resolution of inflammation: a new therapeutic frontier.

Authors:  James N Fullerton; Derek W Gilroy
Journal:  Nat Rev Drug Discov       Date:  2016-03-29       Impact factor: 84.694

5.  Role of SOCS2 in modulating heart damage and function in a murine model of acute Chagas disease.

Authors:  Lisia Esper; Danilo Roman-Campos; Aline Lara; Fatima Brant; Luisa L Castro; Andreia Barroso; Ronan Ricardo S Araujo; Leda Q Vieira; Shankar Mukherjee; Eneas Ricardo M Gomes; Nazareth N Rocha; Isalira P R Ramos; Michael P Lisanti; Camila F Campos; Rosa M E Arantes; Silvia Guatimosim; Louis M Weiss; Jader Santos Cruz; Herbert B Tanowitz; Mauro M Teixeira; Fabiana S Machado
Journal:  Am J Pathol       Date:  2012-05-29       Impact factor: 4.307

6.  Lipoxin A4 inhibits NF-κB activation and cell cycle progression in RAW264.7 cells.

Authors:  Yong-Hong Huang; Hong-Mei Wang; Zhen-Yu Cai; Fang-Yun Xu; Xiao-Yan Zhou
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

Review 7.  AHR-mediated immunomodulation: the role of altered gene transcription.

Authors:  Nancy I Kerkvliet
Journal:  Biochem Pharmacol       Date:  2008-11-27       Impact factor: 5.858

8.  Time-Course Study of the Transcriptome of Peripheral Blood Mononuclear Cells (PBMCs) from Sheep Infected with Fasciola hepatica.

Authors:  Cristian A Alvarez Rojas; Jean-Pierre Scheerlinck; Brendan R E Ansell; Ross S Hall; Robin B Gasser; Aaron R Jex
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

9.  TLTF in cerebrospinal fluid for detection and staging of T. b. gambiense infection.

Authors:  Maha-Hamadien Abdulla; Moiz Bakhiet; Veerle Lejon; Jan Andersson; James McKerrow; Omar Al-Obeed; Robert A Harris
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.